Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurogene Inc. filings document a clinical-stage biotechnology issuer developing genetic medicines for rare neurological diseases. Recent 8-K reports furnish operating results, corporate presentations, clinical and regulatory updates for NGN-401 in Rett syndrome, and material-event disclosures tied to board appointments and executive compensation arrangements.
The company's proxy materials cover director elections, board committee matters, executive compensation, equity awards, pay-versus-performance disclosure, and stockholder voting procedures. Together, the filings describe Neurogene's governance framework, common-stock compensation practices, and formal disclosures around its gene-therapy pipeline and financial condition.
Neurogene Inc. director Woods Keith received a stock option grant to acquire 15,400 shares of common stock at an exercise price of $32.30 per share. The option was granted as a compensation award and vests in equal monthly installments through January 16, 2027, conditioned on continued service. Following this grant, Woods holds 15,400 stock options expiring on January 16, 2034.
Neurogene Inc. director Keith Woods received a fully vested stock option grant covering 7,700 shares of common stock. The option has an exercise price of $42.59 per share and expires on June 14, 2034. Following this award, he holds 7,700 stock options directly.
Neurogene Inc. director Keith Woods received a fully vested non-qualified stock option grant. The award covers 12,050 options, each giving the right to buy one share of common stock at an exercise price of $20.40 per share, expiring on June 12, 2035. Following this compensation-related grant, Woods holds 12,050 derivative securities directly, with no open-market share purchases or sales reported in this filing.
Neurogene Inc. director Woods Keith filed an amended Form 3, which is the initial statement of beneficial ownership for insiders. This amendment reports no share purchases, sales, option exercises, or other equity transactions, and shows no derivative securities or other holdings disclosed in this filing.
Neurogene Inc. has completed dosing in Embolden, its registrational trial of NGN-401, an investigational one-time gene therapy for Rett syndrome. The company exceeded its initial 20-participant target by dosing 25 patients after strong community demand, with a pre-specified intent-to-treat population of 24 for the primary analysis.
At the 1E15 vg dose, NGN-401 has been generally well-tolerated; as of June 7, 2026, 35 treated participants across trials showed no cases of hemophagocytic lymphohistiocytosis. Interim Phase 1/2 data in 10 participants reported multidomain, durable functional gains, with 35 developmental milestones achieved and 88% improving on the CGI-I scale.
Embolden’s primary endpoint requires a 33% minimum response rate, or 8 of 24 participants, at 12 months to support a planned Biologics License Application. Neurogene expects updated Phase 1/2 data in mid-2026 and topline Embolden results in the second half of 2027.
Neurogene Inc. reported the results of its 2026 annual stockholder meeting. Stockholders representing 11,387,407 common shares, about 72.92% of voting power, were present, establishing a quorum. Two Class III directors, Robert Baffi and Rohan Palekar, were elected to serve until the 2029 annual meeting.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers and ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026. In a separate advisory vote, investors expressed a preference for annual advisory votes on executive pay, and the company plans to hold them every year.
Neurogene Inc. reported first quarter 2026 results while advancing its lead Rett syndrome gene therapy, NGN-401. About 90% of participants have been dosed in the Embolden registrational trial, and dosing is expected to be completed in the second quarter of 2026. NGN-401 at the 1E15 vg dose has been generally well-tolerated across the Phase 1/2 trial and Embolden, with no cases of hemophagocytic lymphohistiocytosis reported as of May 11, 2026.
Interim Phase 1/2 data as of October 30, 2025 showed multidomain, durable functional gains across fine motor, gross motor and communication, with 35 developmental milestones gained and 88% of participants achieving improved CGI-I scores. Caregiver testimonials highlighted meaningful improvements in daily living and quality of life.
Financially, Neurogene held $243.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, which is expected to fund operations through the first quarter of 2028. R&D expenses rose to $25.2 million from $17.8 million year over year, driven mainly by NGN-401 clinical and CMC costs, while G&A expenses held at $8.2 million. Net loss widened to $30.9 million from $22.6 million as the company invested in its Rett program and early commercial-readiness activities.
Neurogene Inc. reported first quarter 2026 results while advancing its lead Rett syndrome gene therapy, NGN-401. About 90% of participants have been dosed in the Embolden registrational trial, and dosing is expected to be completed in the second quarter of 2026. NGN-401 at the 1E15 vg dose has been generally well-tolerated across the Phase 1/2 trial and Embolden, with no cases of hemophagocytic lymphohistiocytosis reported as of May 11, 2026.
Interim Phase 1/2 data as of October 30, 2025 showed multidomain, durable functional gains across fine motor, gross motor and communication, with 35 developmental milestones gained and 88% of participants achieving improved CGI-I scores. Caregiver testimonials highlighted meaningful improvements in daily living and quality of life.
Financially, Neurogene held $243.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, which is expected to fund operations through the first quarter of 2028. R&D expenses rose to $25.2 million from $17.8 million year over year, driven mainly by NGN-401 clinical and CMC costs, while G&A expenses held at $8.2 million. Net loss widened to $30.9 million from $22.6 million as the company invested in its Rett program and early commercial-readiness activities.
Neurogene Inc. reported a larger net loss for the three months ended March 31, 2026 as it increased investment in its gene therapy pipeline. Net loss was $30.9 million compared with $22.6 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $25.2 million from $17.8 million, primarily reflecting increased clinical and manufacturing costs for NGN‑401, its Rett syndrome program. General and administrative expenses were stable at $8.2 million. Interest income declined as short‑term investments decreased and yields softened.
Neurogene ended March 31, 2026 with $243.2 million in cash, cash equivalents and short‑term investments and used $26.1 million of cash in operating activities during the quarter. Management expects existing capital to fund obligations for at least one year from the financial statement issuance date while it advances NGN‑401 and other early discovery efforts.
Neurogene Inc. reported a larger net loss for the three months ended March 31, 2026 as it increased investment in its gene therapy pipeline. Net loss was $30.9 million compared with $22.6 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $25.2 million from $17.8 million, primarily reflecting increased clinical and manufacturing costs for NGN‑401, its Rett syndrome program. General and administrative expenses were stable at $8.2 million. Interest income declined as short‑term investments decreased and yields softened.
Neurogene ended March 31, 2026 with $243.2 million in cash, cash equivalents and short‑term investments and used $26.1 million of cash in operating activities during the quarter. Management expects existing capital to fund obligations for at least one year from the financial statement issuance date while it advances NGN‑401 and other early discovery efforts.
Neurogene Inc. director and President/CFO Christine Mikail Cvijic reported two open‑market sales of common stock totaling 9,600 shares on May 6, 2026. The transactions were executed at weighted average prices of $30.0732 and $32.4358 per share.
According to a footnote, these sales were made under a Rule 10b5‑1 trading plan adopted on August 18, 2025, and the shares sold were held jointly with her spouse, David Cvijic. After the transactions, she directly holds 93,640 shares, including 10,635 restricted stock units vesting on March 13, 2027; 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028; and 22,000 restricted stock units vesting annually on February 20, 2027, 2028 and 2029. Of the remaining shares, 9,600 are held jointly with her spouse.
Neurogene Inc. reported that Chief Commercial Officer Christina Shafer received a grant of non-qualified stock options covering 120,000 shares of common stock at an exercise price of $28.94 per share. One quarter of these options will vest on April 20, 2027, with the remaining three quarters vesting in equal monthly installments on the 20th of each month through April 20, 2030, contingent on her continued service. Following this grant, she holds 120,000 derivative securities directly.